---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009363"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:33:59.933477+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Capricor Q1 2023 net loss $7.8M; HOPE-3 DMD trial interim analysis on track for Q4 2023

## Summary
- Net loss $7.8M ($0.31 per share) flat YoY; revenue $3.0M from Nippon Shinyaku deal vs zero prior year.
- Cash, equivalents and marketables $45.2M; runway into Q4 2024, excludes milestone payments.
- HOPE-3 Phase 3 for CAP-1002 in DMD: 13 active sites, targeting full enrollment by H2 2023, interim analysis Q4 2023.
- 24-month HOPE-2 open-label extension data planned for presentation in Q2 2023.
- Received $12M upfront from Japan partner Nippon Shinyaku; potential milestones up to ~$89M plus revenue share.

## SEC filing metadata
- accession: 0001558370-23-009363
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837023009363/0001558370-23-009363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837023009363/capr-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009363
- JSON: https://secwatch.observer/filing/0001558370-23-009363.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009363.txt

## Key facts
- Earnings Releases
  CAPRICOR THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: revenue approximately $3.0 million, net income approximately $7.8 million, or $0.31 per share, EPS $0.31 per share.
  - Period: first quarter ended March 31, 2023
  - Revenue: approximately $3.0 million
  - Net income: approximately $7.8 million, or $0.31 per share
  - EPS: $0.31 per share
  - Result: reported results
  source text: U.S. Exclusive Commercialization and Distribution Agreement received from Nippon Shinyaku in the first quarter of 2022. Revenues for the first quarter of 2023 were approximately $3.0 million compared with zero for the first quarter of 2022. Operating expenses: Total operating expenses for the first quarter of 2023 were approximately $11.2 million compared with
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133869/000155837023009363/0001558370-23-009363-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.